Brilliantly.co IG Live with Mammogen.bio

2 June 2021

Mammogen is a woman-led biotechnology company and we're using data, tech, science and personal experience to shatter complacency.

Founder, Marty Keiser, and CEO, Liz Cormier-May, share their plans to create an end-to-never-end community for women with breast cancer.

3 November 2026
November 3, 2026 | In the News | Forbes Mammogen has been featured in Forbes in an article by Geri Stengel exploring the company's mission to transform breast cancer detection through innovative RNA-based blood testing. The feature highlights Mammogen's co-founder and CEO, Elizabeth Cormier-May, and her vision for making earlier breast cancer detection more accessible, particularly for women with dense breast tissue. At the center of the story is genTRU-breast™ , Mammogen's investigational blood-based diagnostic designed to complement existing breast imaging and provide additional biological insights that may help inform clinical decisions. The Forbes article also explores Mammogen's Series A financing of up to $30 million, its approach to affordability and patient access, and its ongoing commitment to prospective clinical validation. A major focus is the KATELYN-ERIN clinical study, designed to enroll approximately 2,600 women to further evaluate the performance of genTRU-breast™. As Mammogen continues advancing its technology toward clinical integration, the Forbes feature brings attention to an important challenge in women's health: improving access to meaningful information that can support earlier detection and more informed care. Read the full Forbes feature: Mammogen Bets Women Will Pay $500 For A Breast Cancer Blood Test Originally published by Forbes on November 3, 2026. Written by Geri Stengel. This summary was independently prepared by Mammogen. genTRU-breast™ is under clinical development, and prospective validation is ongoing.
27 October 2026
BioSpace | October 27, 2026 Mammogen has announced a clinical research partnership with MammoLink, a specialized women's health imaging provider, to expand community access to innovative breast cancer detection technologies. Through this collaboration, MammoLink will participate in Mammogen's KATELYN-ERIN clinical trial, a prospective study involving approximately 2,600 women. The partnership will leverage MammoLink's mobile 3D mammography network across Florida to evaluate Mammogen's genTRU-breast™ blood-based RNA assay alongside traditional breast imaging. The initiative represents an important step toward integrating molecular diagnostics with community-based breast care, with the goal of improving accessibility and supporting earlier breast cancer detection, particularly for women with dense breast tissue. Click Here to Read the Full Article on BioSpace
23 October 2026
23 October 2026 America's Small Business Network (ASBN) | October 23, 2026 Mammogen CEO and Co-Founder Liz Cormier-May was featured on ASBN's The Female Founder Show, discussing the company's mission to advance breast cancer detection through innovative RNA-based blood testing. During the interview, Cormier-May highlighted the challenges women with dense breast tissue face with traditional mammography and explained how Mammogen's genTRU-breast™ blood-based assay is being developed to provide additional information that could support earlier detection. Cormier-May also shared the personal experiences behind Mammogen's founding, the challenges of advancing innovation in women's health, and her advice for aspiring female entrepreneurs. Click Here to Read the Full Article and Watch the Interview →